Peptide Compounding Compliance Checklist: What You Need Before You Start

Before You Compound Your First Peptide

Evaluating peptide compounding requires a substance-specific regulatory review; adding it to a facility is not as simple as ordering API and writing a formula. Peptides require specific handling, documentation, and quality controls that go beyond standard compounding operations. This checklist covers every area you need to address before your first peptide batch.

1. Supplier Qualification

Peptide APIs must be sourced from qualified suppliers, and the qualification process for peptide suppliers is more rigorous than for traditional compounding chemicals.

• FDA registration: Verify that your API supplier is registered with the FDA as a drug substance manufacturer. Request their FDA Establishment Identifier (FEI) number and confirm it is current.
• Supplier audit: Conduct a documented supplier qualification audit — either on-site or via a detailed questionnaire — covering their manufacturing processes, quality systems, and testing capabilities specific to peptide synthesis.
• Quality agreement: Execute a formal quality agreement specifying purity requirements, identity testing methods, stability data obligations, change notification procedures, and complaint handling processes.
• Backup suppliers: Identify and qualify at least one alternate supplier for each peptide you plan to compound. Supply chain disruptions are common with specialty APIs, and you cannot compound without qualified material.

2. Certificate of Analysis (CoA) Requirements

Every lot of peptide API received must be accompanied by a Certificate of Analysis that meets specific criteria. Your receiving SOPs should include verification of the following:

• Identity testing: The CoA must include results from an identity test (typically HPLC or mass spectrometry) confirming the peptide sequence matches the expected compound.
• Purity: Total purity (typically ≥95% for compounding-grade peptides) with impurity profiles identifying any individual impurity above 0.5%.
• Residual solvents: Testing per USP <467> for residual solvents used in synthesis (TFA, acetonitrile, DMF are common in peptide manufacturing).
• Endotoxin testing: For peptides intended for injectable preparations, endotoxin testing per USP <85> must be documented on the CoA.
• Microbial limits: Bioburden testing results per USP <61> and <62>.
• Storage and expiration: Manufacturer-recommended storage conditions and expiration date for the API lot.

Critically, you must also perform independent identity verification testing on each lot received, regardless of what the supplier's CoA states. This is a USP and FDA requirement that cannot be waived.

3. Standard Operating Procedures

Peptide compounding requires several new SOPs or significant revisions to existing ones. At minimum, you need documented procedures for:

• Peptide API receiving and storage: Temperature-controlled storage requirements (most peptides require -20°C or colder for long-term storage), light protection, and humidity controls.
• Peptide reconstitution: Step-by-step procedures for reconstituting lyophilized peptides, including diluent selection, mixing technique (gentle swirling, never vortexing), and visual inspection criteria.
• Potency calculations: Peptide potency calculations account for salt form, water content, and peptide content percentage — this is different from standard ingredient calculations and must be explicitly documented.
• Beyond-use dating (BUD): BUD assignment based on USP <797> requirements, with supporting stability data. Many peptide preparations have shorter BUDs than traditional compounds due to degradation pathways.
• In-process quality checks: pH verification, visual inspection for particulates, and osmolality testing for injectable preparations.
• Adverse event monitoring: Procedures for detecting, documenting, and reporting adverse events associated with compounded peptide preparations.

All SOPs must go through your formal review and approval workflow with documented electronic signatures before any compounding occurs. Version control and employee acknowledgment tracking are essential for inspection readiness.

4. Environmental Monitoring Considerations

Peptide compounding does not change your cleanroom classification requirements — sterile peptide preparations must still be compounded in ISO 5 environments with appropriate buffer and ante room controls. However, there are additional considerations:

• Temperature monitoring: If you are storing peptide APIs in dedicated freezers, those units must be on your continuous environmental monitoring system with documented excursion alerts and response procedures.
• Dedicated equipment: Consider whether peptide compounding equipment (balances, mixing vessels) should be dedicated or whether cleaning validation is sufficient to prevent cross-contamination.
• Viable monitoring frequency: Review whether your current viable air and surface sampling frequency is adequate given the added compounding activity in your cleanrooms.

5. Personnel Training Requirements

Staff involved in peptide compounding need specific training beyond standard aseptic technique competencies:

• Peptide chemistry basics: Understanding of amino acid sequences, peptide bond stability, common degradation pathways (oxidation, deamidation, aggregation), and how handling affects product quality.
• Reconstitution technique: Hands-on training in peptide reconstitution with documented competency assessment — improper mixing is one of the most common sources of peptide product failure.
• Potency calculations: Demonstrated competency in peptide-specific potency calculations, with documented assessment results.
• Cold chain management: Training on proper handling of temperature-sensitive APIs, including transfer procedures from freezer to compounding area and time-out-of-storage limits.

All training must be documented with completion dates, assessment scores, and trainer signatures. Competency reassessment intervals should align with your facility's USP <797> category (Category 2 or Category 3) frequency requirements.

6. Documentation and Record-Keeping

Ensure your batch record templates are updated to capture peptide-specific information: API lot number, CoA reference, peptide content percentage used in calculations, reconstitution observations, and BUD justification. Every step should have a corresponding signature and timestamp. Your audit trail system must be 21 CFR Part 11 compliant, capturing who performed each action, when, and any changes made to records after initial entry.